Weight Reduction Surgery and Ovarian Function

The Effect of Weight Reduction Surgery on Ovarian Function in Obese Anovulatory Patients

This study will investigate the role of weight reduction surgery on the reproductive performance of obese women with ovulation problems. It is hypothesized that surgery offered when other methods of weight reduction have failed, may help restore ovulation.

Study Overview

Status

Completed

Conditions

Detailed Description

We aim to recruit 30 patients suffering from chronic anovulation, with a body mass index of 35 or more, who failed to achieve weight reduction with other methods such as orlistat, metformin, diet and exercise.

Patients will be approached by one of the investigators in the infertility clinics and the assisted conception unit of the Royal Hallamshire hospital. Consent will be obtained by one of the designated investigators. The consent form has been designed in accordance with the guidelines of the central office for research and ethics committees (COREC). A patient information leaflet will be supplied and has been designed according to the COREC guidelines.

Patients will have a baseline history, clinical examination, hormonal profile (FSH/LH, fasting Insulin/glucose ratio, androgen profile, day 21 serum progesterone, serum leptin and ghrelin levels) ultrasound examination (ovarian volume and antral follicle count), including Doppler blood flow study (ovarian stromal velocity).

Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months. At each visit the following will be recorded:

  1. Weight, menstrual diary.
  2. Hormonal profile (FSH/LH, fasting Insulin/glucose ratio, androgen profile, day 21 serum progesterone, serum leptin and ghrelin levels).
  3. Doppler of ovarian stroma (Pulsitility index, Peak velocity), ovarian volume and antral follicle count
  4. Review of symptomatology especially androgenic symptoms.

End point:

Completion of six months follow up.

Study Type

Observational

Enrollment (Anticipated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sheffield, United Kingdom, S10 2SF
        • Jessop Wing, Royal Hallamshire Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Obese anovulatory women.

Description

Inclusion Criteria:

  1. Anovulation or irregular ovulation as determined by the following clinical or laboratory features:

    • Clinical:

      i. Irregular cycles (not 25-35 days) ii. Amenorrhoea (more than six months).

    • Biochemical: Day 21 or midleuteal serum progesterone of less than 30mmol/l.
  2. BMI of 35 or more.
  3. Age between 18 and 45.

Exclusion Criteria:

  1. Contraindication for bypass surgery:

    i. Medically unfit ii. Psychologically unfit iii. Strong family history of gastric cancer

  2. Insulin dependant diabetes or patients on oral hypoglycaemics. Insulin resistance and impaired glucose tolerance however, are not exclusion criteria.
  3. Concomitant endocrine disorders including thyroid disease and Cushing syndrome.
  4. Patients on steroid therapy.
  5. Patients who have had one or both ovaries removed.
  6. Biochemical evidence of ovarian failure i.e. FSH of 20 IU or more.
  7. Patients who have had hysterectomy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Professor TC Li, FRCOG,MD, STH
  • Study Chair: Professor William Ledger, FRCOG,D Phil, Sheffield University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2006

Study Completion (Actual)

February 1, 2008

Study Registration Dates

First Submitted

February 15, 2006

First Submitted That Met QC Criteria

February 15, 2006

First Posted (Estimate)

February 16, 2006

Study Record Updates

Last Update Posted (Estimate)

July 20, 2011

Last Update Submitted That Met QC Criteria

July 19, 2011

Last Verified

July 1, 2011

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe